ArticleTranslational cancer research2016
Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma.
Article in Translational cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Human biomarker navigator.iMeta · 2026Review
- Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC.Cancers · 2021Review
- Decision-making in active surveillance in kidney cancer: current trends and future urine and tissue markers.World journal of urology · 2021Review
- Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression.Frontiers in oncology · 2021Article
- Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic 'Choosing Wisely' campaign: a narrative review.Translational cancer research · 2020Article
- Combination drug regimens for metastatic clear cell renal cell carcinoma.World journal of clinical oncology · 2020Review
- Taking a SPOP at renal cell carcinoma - unraveling a novel pathway for Tumor progression in clear cell RCC.EBioMedicine · 2020Article
- Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system.Annals of translational medicine · 2019Article
- Role of the androgen signaling axis in genitourinary malignancies.Translational cancer research · 2018Article
- Data-Driven Methods for Advancing Precision Oncology.Current pharmacology reports · 2018Article
- Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.International urology and nephrology · 2017Article
- Renal cell carcinoma: the search for a reliable biomarker.Translational cancer research · 2017Article
- Renal cell carcinoma: molecular characterization and evolving treatment paradigms.Current opinion in oncology · 2017Article
- Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate.World journal of clinical oncology · 2017Article
- Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Frontiers in oncology · 2017Review
- Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis.Journal of kidney cancer and VHL · 2017Article
- Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The recent FDA approval of multiple new pharmaceutical agents for metastatic renal cell carcinoma (RCC) has left physicians with several options for first- and second- line therapy. With limited head-to-head comparisons, however, there is a paucity of evidence to recommend the use of one agent over another. To address this knowledge gap, Voss et al. identified serum biomarkers from specimens collected during the RECORD-3 trial, a comparative study of first-line sunitinib versus first-line everolimus. Of the biomarkers identified, the 5 most strongly associated with first-line everolimus progression-free survival (PFS1L) were combined to form a composite biomarker score (CBS). The CBS was significantly associated with everolimus PFS1L in multivariate regression analysis. This study is an example of the additional value offered by a randomized trial with prospective biospecimen collection and a significant step towards identifying predictive biomarkers for the treatment of metastatic RCC. As further comparative trials are performed, it will be essential that biomarkers are appropriately identified and validated in order to further the goal of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.